Menu
Search
|

Menu

Close
X

Auris Medical Holding Ltd EARS.OQ (NASDAQ Stock Exchange Capital Market)

2.64 USD
-- (--)
As of Jul 17
Previous Close 2.64
Open --
Volume --
3m Avg Volume 38,866
Today’s High --
Today’s Low --
52 Week High 39.20
52 Week Low 2.42
Shares Outstanding (mil) 1.90
Market Capitalization (mil) 5.03
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, CHF)
FY18
0
FY17
0
FY16
0
EPS (CHF)
FY18
-21.402
FY17
-114.010
FY16
-178.634
*Note: Units in Millions of Swiss Francs
**Note: Units in Swiss Francs

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.16
Price to Sales (TTM)
vs sector
--
8.16
Price to Book (MRQ)
vs sector
1.27
4.38
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
39.33
18.17
LT Debt to Equity (MRQ)
vs sector
0.00
13.01
Return on Investment (TTM)
vs sector
-180.83
12.64
Return on Equity (TTM)
vs sector
-1,545.80
17.19

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Bahnhofstrasse 21
ZUG   ZUG   6300

Phone: +4161.2011350
Site:

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.

SPONSORED STORIES